Madopar (Benserazide, Levodopa)

Levodopa is a precursor that the brain converts into dopamine, replenishing deficient neurotransmitter levels. Benserazide blocks peripheral conversion of levodopa, ensuring more of the drug reaches the central nervous system where it can be transformed into dopamine.

The appropriate dose of Madopar is individualized and set by the prescribing healthcare professional based on the patient’s condition, response, and tolerance. Dosage adjustments are made during treatment to balance efficacy and side‑effects.

Safety data for Madopar in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified clinician.

To order Madopar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Madopar combines levodopa with benserazide, offering higher central dopamine delivery than levodopa alone. Compared with dopamine agonists, it often provides stronger symptom control but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on disease stage, patient age and tolerance.

Madopar tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Madopar is taken orally with a full glass of water. It is usually administered several times daily, and dosing times may be adjusted around meals because high‑protein foods can affect absorption. Patients should follow the prescribing clinician’s instructions regarding timing and food.

Serious risks include severe hypotension, hallucinations or psychosis, cardiac arrhythmias, neuroleptic malignant syndrome, and rare but life‑threatening allergic reactions. Any sudden changes in mental status, blood pressure or heart rhythm should prompt immediate medical evaluation.

Madopar is contraindicated in patients with known hypersensitivity to levodopa or benserazide, those taking non‑selective MAO inhibitors, and individuals with narrow‑angle glaucoma or severe cardiovascular disease where dopamine‑mediated effects could be harmful. Clinicians should assess each patient’s medical history before prescribing.